Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab with Chemoradiotherapy in Locally Advanced ESCC
NCT06421376Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Bispecific Antibodies
- Drugs
- cadonilimab
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Event-free survival at 1 year. Started May 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Inductive chemoimmunotherapy+chemoradiotherapy±surgery
Induction with Cardonilizumab/chemo -> CCRT -> Surgery or Maintenance Cardonilizumab
03
Endpoints
Primary
Event-free survival
Secondary
Overall survival
Adverse events
Locoregional recurrence free survival
Distant metastasis free survival
Beyond the preview
Go deeper on NCT06421376.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421376.